Increased Plasma Indoleamine 2,3-Dioxygenase Activity and Interferon-γ Levels Correlate with the Severity of Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation  by Xu, Jinhuan et al.
Biol Blood Marrow Transplant 19 (2013) 196e201American Society for Blood
ASBMT
and Marrow TransplantationIncreased Plasma Indoleamine 2,3-Dioxygenase Activity
and Interferon-g Levels Correlate with the Severity of Acute
Graft-versus-Host Disease after Allogeneic Hematopoietic
Stem Cell Transplantation
Jinhuan Xu, Jia Wei, Xianmin Zhu, Xiaomei Zhang, Jun Guan, Jiaqi Wang,
Jin Yin, Yi Xiao, Yicheng Zhang*
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030,
ChinaArticle history:
Received 10 June 2012
Accepted 15 October 2012
Key Words:
Acute graft-versus-host disease
Indoleamine 2,3-dioxygenase,
IFN-g
Hematopoietic stem cell
transplantationFinancial disclosure: See Acknowl
* Correspondence and reprint
Department of Hematology, Ton
Huazhong University of Science a
Wuhan 430030, China.
E-mail address: yczhang@tjh.tjm
1083-8791/$ e see front matter 
http://dx.doi.org/10.1016/j.bbmt.20a b s t r a c t
Indoleamine 2,3-dioxygenase (IDO) is a rate-limiting enzyme for the tryptophan catabolism that plays an
important role in the induction of immune tolerance. To evaluate the expression levels of IDO and interferon
(IFN)-g in patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT) and to identify
the correlation between IDO activity, IFN-g, and acute graft-versus-host disease (aGVHD), we measured IDO
mRNA expression in peripheral blood mononuclear cells in 89 allo-HSCT patients by reverse transcription-
polymerase chain reaction. The IDO activity in plasma was also performed by reverse-phase high-perfor-
mance liquid chromatography; plasma IFN-g was detected by a standard enzyme-linked immunosorbent
assay. IDO mRNA was detected in 55 of 74 patients (74.32%) with aGVHD. Of patients without aGVHD, only 2
of 26 expressed IDO mRNA (7.69%); none of 8 healthy volunteers was positive for IDO expression. Plasma IDO
activity was much higher in aGVHD patients than in those without aGVHD (4.74  3.35 vs 1.79  1.02,
respectively; P < .0001) or in healthy control subjects (4.74  3.35 vs 1.77  .22; P < .0001). Patients with
severe (grade III/IV) aGVHD had much higher IDO activity than those with mild (grade I/II) aGVHD
(6.57  3.34 vs 2.46  1.41; P < .0001). Meanwhile, there was a signiﬁcant increase in plasma IFN-g level in
aGVHD patients (P ¼ .0043). IDO activity decreased after alleviation of aGVHD, whereas ﬂuctuation of plasma
IDO was also observed upon the recurrence of aGVHD. Plasma IDO activity was correlated with the level of
plasma IFN-g (r ¼ .8288; P < .0001). Using receiver-operating characteristic curves analysis, the sensitivity
and speciﬁcity for evaluation of aGVHD were determined. The area under the curve of IDO activity was higher
than that of IFN-g (.852 vs .694) with a sensitivity and speciﬁcity for IDO of 81% and 78%, respectively,
whereas the sensitivity and speciﬁcity for IFN-g were 41% and 93%, respectively. IDO mRNA was expressed in
blood mononuclear cells of patients with aGVHD. Plasma IDO activity was elevated in aGVHD patients and
was correlated with the severity of aGVHD. In combination with plasma IFN-g, IDO activity may represent
a potential biomarker for the diagnosis and evaluation of aGVHD after allo-HSCT. Intervention of the IDO
pathway may also represent an alternative way to overcome steroid-resistant aGVHD.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) is one of the most effective ways to cure hematopoi-
etic malignancies, but acute graft-versus-host disease
(aGVHD) remains the major challenge because it may incur
HSCT-related complications and transplantation failure.
Currently, no reliable instrumental or laboratory tests are
available to evaluate the occurrence and the severity of
aGVHD, so the implementation of optimal treatment strate-
gies relies solely on clinical manifestation and subjective
judgment. Finding objective parameters that may predict
and distinguish aGVHD from other complications remains an
important goal in the ﬁeld of allo-HSCT. aGVHD is a typical
donor type I helper T lymphocyte (T helper, type I, Th1)-
mediated allogeneic immune response; Th1 cytokines,
especially interferon (IFN)-g produced by Th1 cells, are
involved in several aspects of aGVHD pathophysiologyedgments on page 200.
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12.10.013[1].The role of IFN-g in GVHD is dichotomous. On one hand, it
plays key roles in the ampliﬁcation of immune response and
tissue damage in aGVHD [2]: In several studies, increased
serum levels of IFN-g were associated with the severity of
aGVHD in mice [3-5]. On the other hand, IFN-g mediates
GVHD-associated immunosuppression in experimental
GVHD. Brok et al. found that a high dosage of IFN-g imme-
diately after bone marrow transplantationwas crucial for the
prevention of aGVHD in a murine bone marrow trans-
plantation model [6]. In view of its paradoxical roles in the
pathogenesis of aGVHD and its spatiotemporal expression
pattern, IFN-g is not routinely measured in the circum-
stances of clinical aGVHD. Theoretically, it is possible that
IFN-gerelated substances such as molecules in the down-
stream pathway of IFN-g could be detected in case of aGVHD.
Indoleamine 2,3-dioxygenase (IDO) is an intracellular
heme-containing enzyme that catalyzes the ﬁrst and rate-
limiting step of tryptophan catabolism along the kynur-
enine pathway. IDO is induced during inﬂammation by
inﬂammatory cytokines; in particular, Th1 cytokine IFN-g is
the strongest inducer of IDO expression [7,8]. Tryptophan
deﬁciency and/or metabolite concentration excesses
have immunomodulatory effects, including suppression ofTransplantation.
Table 1
Patient Characteristics
Characteristics No. of Patients with Characteristic for
Indicated Grade of aGVHD (%)
Grade 0-II Grade III-IV P Value
Total patient No. 58 31 d
Sex
Male 35 (60) 12 (39) .195
Female 23 (40) 19 (61)
Age, y
Median 33 28 .853
Range 3-55 12-42
Disease
AML 21 (36) 10 (32)
ALL 11 (19) 7 (23)
CML 9 (16) 4 (13) .451
MDS 6 (10) 4 (13)
SAA 7 (12) 2 (6)
NHL 3 (5) 2 (6)
Other diseases 1 (2) 2 (6)
Conditioning regimen
Myeloablative 45 (78) 21 (68) .550
Reduced intensity 13 (22) 10 (32)
Donor
Match related 40 (69) 22 (71)
Mismatched related 8 (14) 4 (13) .917
Match unrelated 10 (17) 5 (16)
GVHD prophylaxis
MTXþCSA 37 (64) 16 (52)
MTXþFK506 18 (31) 13 (42) .264
MMFþCSA 3 (5) 2 (6)
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia;
CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; SAA,
severe aplastic anemia; NHL, non-Hodgkin lymphoma; aGVHD, acute graft-
versus-host disease; MTX, methotrexate; CSA, cyclosporine A; FK506,
tacrolimus; MMF, mycophenolate mofetil.
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to apoptosis and inhibition of T cell activation [9]. Based on
these properties, studies have shown that IDO plays a crucial
role in the induction of immune tolerance during infection,
maternal-fetal acceptance, tumor immunity, and trans-
plantation [7,10,11]. In addition, IDO activity is upregulated in
many Th1-mediated autoimmunity diseases, such as exper-
imental autoimmune encephalomyelitis, autoimmune dia-
betes in nonobese diabetic mice, and collagen-induced
arthritis [12-14]. Jasperson et al. showed that IDO/ or IFN-
gR/ mice experienced more severe aGVHD after alloge-
neic bone marrow transplantation because these recipients
were unable to produce IDO as an important counter-
regulatory mechanism [15]. In allogeneic bone marrow
transplantation recipients, increased IDO expression has
been reported in monocytes, intestinal epithelial cells, and
plasma from patients with aGVHD [9,16,17]. Landfried et al.
found that tryptophan metabolite levels were elevated in
the urine of patients with GVHD, and increased expression
of IDO mRNA was detected in intestinal biopsies from
patients with severe GVHD. Levels of kynurenine and IDO
mRNA were correlated with GVHD severity [18]. Although
these studies indicate that IDO expression is upregulated
in the target organ and plasma of aGVHD patients, system-
atic analyses and dynamic monitoring methods are still
lacking. Therefore, we collected peripheral blood samples
from patients before and after HSCT to measure the
concentrations of kynurenine and tryptophan in plasma and
to detect the IDO mRNA expression in peripheral blood
mononuclear cells. Our results indicate that the plasma IDO
activity is correlated with the severity and progression of
aGVHD.
MATERIALS AND METHODS
Patients
A total of 89 patients undergoing allo-HSCT from June 2009 to January
2012 were enrolled in this study at the Department of Hematology, Tongji
Hospital, Tongji Medical College, Huazhong University of Science and
Technology. This study was approved by the Medical Ethics Committee of
the Tongji Hospital. All patients gave written informed consent to sampling
of blood and collection of clinical data in accordance with the Declaration
of Helsinki. The characteristics of all selected patients are summarized
in Table 1.
Specimens
Blood samples from 89 patients receiving allo-HSCT and 8 healthy
volunteers were collected, separated, and stored for further study. All
samples were collected in EDTA tubes from patients on the day before HSCT
and on days 30 and 60 post-HSCT. For patients with aGVHD, blood samples
were also collected at the onset of aGVHD and after treatment. Samples from
patients with infection were excluded from this study. The diagnoses and
aGVHD grades were previously recorded based on patients’ clinical and
pathological features and laboratory data, in accordance with previously
published criteria [19]. Peripheral blood was centrifuged at 1,500 rpm for
5 minutes to separate the plasma, which was then divided into 2 parts. One
part was stored at 80C in preparation for the measurement of IFN-g, and
the other part was deproteinized with an equal volume of .5N perchloric
acid for 10 minutes on ice and centrifuged at 15,000 rpm for 10 minutes to
recover the supernatant for the measurement of kynurenine and
tryptophan.
Measurement of Kynurenine and Tryptophan Levels
Tryptophan and kynurenine concentrations (mmol/L) in plasma were
measured by reverse-phase high-performance liquid chromatography
(Waters, Milford, MA) as described previously [20]. In brief, the frozen
supernatants were thawed at room temperature and separated on a C18
reversed-phase column; the mobile phase was 15 mmol/L acetic acid/
sodium acetate (pH 4.0) containing 27 mL/L acetonitrile. Tryptophan was
detected by its native ﬂuorescence at 287-nm excitation and 357-nm
emission. Kynurenine was monitored by ultraviolet absorption at 360-nm
wavelength in the same chromatographic run. The plasma kynurenineconcentrations and tryptophan concentrations were twice the values indi-
cated by the high-performance liquid chromatography equipment. The IDO
activity was calculated by dividing the plasma concentration of kynurenine
by that of tryptophan, and the ratio was normalized (100).Determination of Plasma IFN-g Levels
To determine the IFN-g levels and any association between IFN-g and
IDO activity in patients undergoing transplantation, especially in the cases of
aGVHD, plasma IFN-g was measured using enzyme-linked immunosorbent
assay kits (R&D Systems, Minneapolis, MN). Assays were performed
according to themanufacturer’s protocol and read at 450 nm by amicroplate
reader (Bio-Rad, Berkeley, CA).Reverse TranscriptionePolymerase Chain Reaction Analysis of IDO in
Mononuclear Cells
Mononuclear cells were separated by density- gradient centrifugation;
total RNAwas then isolated using a Trizol reagent (Invitrogen, Carlsbad, CA)
and was then reverse transcribed into cDNA using a transcription kit (Fer-
mentas, Thermo-Fisher Scientiﬁc, Barrington, IL) in a total volume of 25 mL at
42C for 60 minutes, extended at 95C for 5 minutes. The cDNA was
ampliﬁed by polymerase chain reaction (PCR) using IDO sense 50-TTTCAC-
CAAATCCACGAT CA-30 and antisense 50-CAGGACGTCAAAGCACTGAA-30
primers. After an initial denaturation step of 5 minutes at 95C, 35 cycles
consisting of 30 seconds at 94C, 30 seconds at 59C, and 45 seconds at 72C
were performed, followed by a ﬁnal extension of 10 minutes at 72C. PCR
products were resolved on 2% agarose gel stained with ethidium bromide
and visualized on a Chemi-Imager 4400 system (Alpha Innotech Co.,
Johannesburg, South Africa).Statistical Analyses
Data are presented as mean standard deviation. IDO activity and IFN-g
levels were analyzed using Kruskal-Wallis, analysis of variance, and Mann-
Whitney U test. Probability values of P< .05 were interpreted as statistically
signiﬁcant. Correlation between IDO activity and IFN-g level was assessed by
linear regression. Multivariable logistic regression was analyzed for patient
characteristics; the receiver-operating characteristic (ROC) analysis was
used to evaluate the sensitivity and speciﬁcity of IDO activity and IFN-g
Figure 1. The IDO mRNA expression detected by RT-PCR in peripheral blood
mononuclear cells. Lanes 1-2: healthy volunteers, lanes 3-4: patients before
infusion of stem cells, lanes 5-7: patients without aGVHD, lanes 8-10: patients
with aGVHD. GAPDH was used as a loading control.
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performed with SPSS 18.0 for Windows (SPSS, Inc., Chicago, IL).
RESULTS
Patient and Sample Characteristics
Of the 89 allo-HSCT patients and 8 healthy volunteers,
a total of 143 blood samples at various time points were
collected and analyzed. Of these patients, 53 exhibited as
grade I or II aGVHD (59.6%), and 31 had grade III or IV aGVHD
(34.8%). During the observation period, 5 patients did not
develop aGVHD (5.6%), and in 22 patients, aGVHD did not
appear within 30 days; however, these patients later devel-
oped acute GVHD. At day 30,we collected blood samples from
these 27 patients and analyzed the data as the non-aGVHD
group. Factors such as age, sex, diagnosis, conditioning
regimen, stem cell donor status, and GVHD prophylaxis
regimen did not inﬂuence IDO levels (Table 1; P > .05).
Expression of IDO mRNA in Peripheral Blood
Mononuclear Cells
Using reverse transcriptase (RT)-PCR, we detected IDO
expression in the peripheral mononuclear cells from most
patients with aGVHD (55 of 74, 74.32%) after allogeneic
transplantation, whereas only 2 of 26 patients without
aGVHD were positive for IDO expression (7.69%). All control
samples from healthy volunteers were negative for IDO
expression. Figure 1 is a representative image of RT-PCR
experiments showing IDO mRNA expression in mono-
nuclear cells from patients with or without aGVHD. However,
for aGVHD patients, the IDO expression levels were not
correlated with the severity of aGVHD (data not shown).
Plasma IDO Activity Correlates with aGVHD Severity
To understand possible roles of IDO in the process of
allogeneic reaction, especially in the setting of aGVHD, we
measured plasma IDO activity before allo-HSCT, at day 30
and day 60 after allo-HSCT, or at aGVHD onset. The IDO
activity in healthy volunteers was 1.77  .22, in patients
before transplantation was 1.50  .70, in patients withoutFigure 2. Comparison of plasma IDO activity in different groups (A and B). Ctl indicate
stem cells; non-aGVHD, no aGVHD at the ﬁrst time of sample draw; aGVHD, patients
Statistical analyses: Kruskal-Wallis, analysis of variance, and Mann-Whitney U test.aGVHD was 1.79  1.02, and in patients with aGVHD was
4.74  3.35. Low levels of IDO activity were detected in
patients without aGVHD at either day 30 or day 60 after allo-
HSCT; these values were similar to those of patients before
transplantation or to healthy donors (Figure 2A; P ¼ .3876
and P ¼ .2979, respectively). Patients with aGVHD exhibited
a signiﬁcant increase in plasma IDO activity compared with
patients without aGVHD (Figure 2A; P < .0001). Further
study showed that plasma IDO activity in patients with grade
III/IV aGVHD (6.57  3.34) was much higher than that of
patients with grade I/II aGVHD (2.46  1.41; P < .0001;
Figure 2B).
Inﬂuence of aGVHD Therapy on Plasma IDO Activity
To investigate whether immunosuppressive therapies
inﬂuence plasma IDO activity and to explore the correlation
between aGVHD severity and IDO activity level, we serially
monitored IDO activity after steroids or other immunosup-
pressive treatments in selected aGVHD patients. For patients
who initially showed increased IDO activity at the onset of
aGVHD, synchronized reduction of plasma IDO activity was
observed in those patients with the alleviation of aGVHD
after effective management with immunosuppressive
therapy. In 4 patients with aGVHD relapse, examinations also
showed the ﬂuctuation of IDO activity (Figure 3). Of these 4
patients, 2 died from refractory aGVHD or severe infection.
Relationship between Plasma IFN-g Levels and aGVHD
and the Correlation of Plasma IFN-g Concentration and
IDO Activity
To determine whether endogenous IFN-g production in
patients with aGVHD is associated with IDO activity and
aGVHD severity, the plasma concentrations of IFN-g were
also measured in patients after allo-HSCT. We observed that
trends of IFN-g levels in aGVHD patients were similar to
those of IDO activity. The mean IFN-g levels in healthy
volunteers was 20.32  5.17 pg/mL, in patients before
transplantation, it was 26.15  11.28 pg/mL, in patients
without aGVHD, it was 30.48  16.47pg/mL, and in patients
with aGVHD, it was 50.10  33.37 pg/mL, there was a signif-
icant increase in aGVHD patients compared with those
without aGVHD (Figure 4A; P ¼ .0043). Moreover, patients
with grade III/IV aGVHD also exhibited higher concentrations
of IFN-g than patients with grade I/II aGVHD (Figure 4B;
P ¼ .0038). In the ROC analysis of plasma IDO activity and
IFN-g levels, the area under the ROC curve for IDO activity
was .852 (95% conﬁdence interval [CI], .773 to .931; P < .000;
Figure 5A), setting the optimal cut-off value at 2.14 gave
a sensitivity of 81% and a speciﬁcity of 78% on the ROCs healthy volunteers; pre-HSCT, blood samples from patients before infusion of
with aGVHD; AU, arbitrary units. Bars indicate the mean values for each group.
Figure 3. The dynamic change of IDO activity in patients with aGVHD. AE, the
IDO activity of patients after engraftment and do not present with aGVHD;
aGVHD, the IDO activity of patients at the onset of aGVHD; CR, the IDO activity
of patients when aGVHD were completely relieved; RE, the IDO activity of
patients when aGVHD recurred.
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was .694 (95% CI, .586-.803; P ¼ .003; Figure 5A), the optimal
cutoff point to predict aGVHD was 50.71 pg/mL, and this
tentative cutoff value gave a sensitivity of 41% and a speci-
ﬁcity of 93% on the ROC curve. A composite ROC curve
analysis of both IDO activity and IFN-g levels showed that the
area under the curve was .849 (95% CI, .770-.929; P ¼ .000;
Figure 5B), and the sensitivity and speciﬁcity were 88% and
70%, respectively. The regression study showed that the
plasma concentration of IFN-g was correlated with IDO
activity (Figure 4C; r ¼ .8288, P < .0001).DISCUSSION
Although the detailed mechanism remains uncertain, the
immunosuppressive property of IDO is widely accepted and
has been explored for its induction of peripheral tolerance,
especially in the area of graft tolerance. Increased IDO activity
has been detected in kidney, corneal, and cardiac trans-
plantation rejection, consistent with its role in transplantationFigure 4. Comparison of the plasma levels of IFN-g in different groups (A and B) and a
the healthy volunteers; pre-HSCT, blood samples from patients before infusion of stem
with aGVHD. Bars indicate the mean values for each group. Statistical analyses: Krusimmune tolerance [21-23]. Jasperson et al. reported in an
experimentalmurine bonemarrow transplantationmodel that
more serious aGVHD in IDO/ mice or IFNgR/ recipients
was recorded after allogeneic bone marrow transplantation
[15]. In the setting of clinical allogeneic bone marrow/periph-
eral stem cell transplantation, increased IDO expression has
been reported in aGVHD with either mRNA expression detec-
ted by RT-PCR or IDO protein detected with enzyme-linked
immunosorbent assay. Systematic analyses and dynamic
monitoring of IDO activity in the plasma of clinical aGVHD
patients, however, are still lacking. As activation of IDO requires
posttranslational modiﬁcation of the central heme element of
the enzyme [24], active IDO then catalyzes the initial and
rate-limiting step of the tryptophan oxidative catabolism
and exhibits immunomodulatory effects through tryptophan
metabolites such as kynurenine excess. Therefore, the IDO
activity (represented by tryptophan metabolites) rather than
IDO mRNA or IDO protein detection most accurately reﬂects
the immunosuppressive function of IDO in vivo.
In the present study, we found that plasma IDO activity
was noticeably elevated in patients with aGVHD. More
importantly, IDO level was correlated with the severity of
aGVHD; patients with grade III/IV aGVHD had signiﬁcantly
higher IDO activity than those with grade I/II aGVHD. These
phenomena are consistent with a recent report by Landfried
et al., who measured IDO activity in 54 patients receiving
allo-HSCT by determining the level of the tryptophan
metabolite kynurenine in urine. The IDO activity (repre-
sented by kynurenine concentration) was associated with
aGVHD severity and treatment-related mortality [18].
Previous research by Zhao et al. [17] and Steckel et al. [9] also
showed that IDO protein and gene expression were elevated
in aGVHD, but only in mild cases. On the contrary, grade III/IV
aGVHD was associated with relatively low IDO levels. This
discrepancy may be partially attributable to the differences
in the methods of assessing IDO expression between the
studies.
Apart from the complexity of diagnosis of aGVHD, eval-
uation of the efﬁcacy of immunosuppressants and the
prognosis in aGVHD present difﬁculties for clinicians.nalysis of the correlation of IDO activity with IFN-g expression (C). Ctl indicates
cells; non-aGVHD, no aGVHD at the ﬁrst time of sample draw; aGVHD, patients
kal-Wallis, analysis of variance, Mann-Whitney U test, and linear regression.
Figure 5. ROC curve analysis of plasma IDO activity and IFN-g levels. (A) Area under the ROC curve for IDO activity and IFN-g levels was .852 (95% CI, .773-.931;
P ¼ .000) and .694 (95% CI, .586-.803; P ¼ .003), respectively. (B) A composite ROC curve of both IDO activity and IFN-g levels; the area under the ROC curve was .849
(95% CI, .770-.929; P ¼ .000).
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shows that IDO activity not only correlates with aGVHD
severity but also with the response of aGVHD to steroids or
other immunosuppressants. IDO activity returns to baseline
level in patients responding to effective treatment. On the
other hand, ﬂuctuation of plasma IDO activity was observed
upon the recurrence of aGVHD. Although this preliminary
study is promising for evaluation of patients with aGVHD,
a large-scale study is needed to validate the result before it
can be widely applied in the clinical setting.
The reasons patients experience severe aGVHDeven in the
presence of high levels of IDO activity remain elusive. As an
initiator and the central mediator in aGVHD, IFN-g has been
established to be the most important Th1-related cytokine in
the development of aGVHD, an inﬂammation similar to
cascade ampliﬁcation. Many other cytokines or inﬂammation
factors may have also been implicated in the process;
although IFN-g is the strongest inducer of IDO expression, the
elevated expression of IDOmay not be able to counterbalance
the induction and aggravation of aGVHD by proinﬂammatory
factors [2-8]. Research by Landfried et al. also support this
hypothesis [18]. IDO activity reﬂects a reactive release of
immunosuppressive mediators in GVHD-related inﬂamma-
tion, which is initiated to counteract the immune reactions.
Obviously, this reactive induction of IDO is insufﬁcient to
control GVHD; more importantly, IDO expression may lag
behind the IFN-g production and appearance of acute rejec-
tion. In the time course of murine GVHDmodels, IFN-g peaks
were found to appear before the clinical symptoms of GVHD
[25,26]. We postulate that intervention of the IDO pathway
ahead of the IFN-g release and the initiation of aGVHD may
prove to be a feasible way to prevent severe aGVHD. In our
murine allogeneic bone marrow transplantation model, we
found that injection of N-(3,4-dimethoxycinnamonyl)
anthranilic acid, a synthetic tryptophan catabolite derivative,
before infusion of grafts was more effective to alleviate
aGVHD (unpublished data).
In summary, the present study shows that patients with
aGVHD have higher levels of IDO activity as assessed by the
plasma concentrations of kynurenine and tryptophan than
non-GVHD subjects. IDO activity and IFN-g levels were
associated with the severity of aGVHD. Both IFN-g and IDO
could be used as biomarkers for diagnosis and evaluation of
aGVHD; nevertheless, IDO is more reliable when the areaunder the curve of ROC, sensitivity, and speciﬁcity are taken
into account. Detecting plasma IDO activity and IFN-g
concentration simultaneously would potentially provide
additive diagnostic information. Intervention of the IDO
pathway may represent an alternative method of preventing
and overcoming aGVHD in high-risk recipients.ACKNOWLEDGMENTS
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